Company Description
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China.
The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain.
Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain.
The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010.
Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 346 |
| CEO | Zhenjiang Yue |
Contact Details
Address: 1098 Foster City Blvd., Suite 106-810 Foster City, California 94404 United States | |
| Phone | 646-367-1747 |
| Website | aoxingpharma.com |
Stock Details
| Ticker Symbol | AOXG |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001060426 |
| CUSIP Number | 16937H106 |
| ISIN Number | US03740A1060 |
| Employer ID | 65-0636168 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zhenjiang Yue | Chairman and Chief Executive Officer |
| Guoan Zhang | Chief Financial Officer, Chief Accounting Officer and Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 17, 2017 | 15-12G | Securities registration termination |
| Oct 6, 2017 | 25 | Filing |
| Oct 5, 2017 | EFFECT | Notice of Effectiveness |
| Sep 29, 2017 | AW | Amendment Withdrawal Request |
| Sep 28, 2017 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Sep 27, 2017 | POS AM | Post-Effective amendments for registration statement |
| Sep 26, 2017 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Sep 25, 2017 | 8-K | Current Report |
| Aug 4, 2017 | 8-K | Current Report |
| Jun 22, 2017 | 8-K | Current Report |